Clinical trials: Community Pneumonia
COVID-19
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Conversational Agent Study
The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations.
- Trial name
- NCT05533359
- Testing
- Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- University of Utah
Pneumonia
CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
The aim of the study described is to measure the degree with which zinc given as adjunct therapy to standard antibiotic treatment during childhood pneumonia reduces the risk of treatment failure and the duration of the illness.
- Trial name
- NCT00148733
- Testing
- Zinc
- Where
- Nepal
- Volunteers
- 2,628 people
- Sponsor
- Centre For International Health
Pneumonia, Respiratory Failure
CPAP Versus HFNO for the Treatment of Acute Hypoxemic Respiratory Failure Due to Community Acquired Pneumonia
the study compares two non-invasive respiratory support modalities ie CPAP and High Flow nasal cannula oxygen for the treatment of severe hypoxemic respiratory failure attributed to Community acquired Pneumonia.
- Trial name
- NCT05755425
- Testing
- CPAP, HFNO
- Where
- 2 sites in Greece
- Volunteers
- 100 people
- Sponsor
- Evangelismos Hospital
Community Acquired Pneumonia
Corticosteroids in Community Acquired Pneumonea
Low dose hydrocortisone IV in patients with CAP fastens recovery of pneumonia and prevents the development of sepsis related complications with a significant reduction in duration of mechanical ventilation
- Trial name
- NCT01228110
- Testing
- Hydrocortison, Saline Solution
- Volunteers
- 80 people
- Sponsor
- Cairo University
Pneumonia, Probiotics
Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia
The study goal is to determine whether oral administration of a probiotic mixture can reduce the incidence of antibiotic-associated diarrhea in patients with community-acquired pneumonia.
- Conditions
- Pneumonia, Probiotics, Diarrhea
- Trial name
- PROBIO (NCT06990568)
- Testing
- Lacidofil
- Volunteers
- 100 people
- Sponsor
- National Health Insurance Service Ilsan Hospital
Community Acquired Pneumonia
A Registry Study on Hospitalized Patients With Community-acquired Pneumonia in Real-life of China
The purpose of this study is to evaluate the disease burden of hospitalized patients with CAP and HCAP in real life of China
- Trial name
- CAP-China (NCT02492425)
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Capital Medical University
Community-Acquired Pneumonia
Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia
The primary objective of the study is to evaluate if the efficacy of an experimental strategy on antibiotic treatment duration based on stopping treatment when stability criteria are reached after at least 48 h of treatment, is…
- Trial name
- CAT-CAP (NCT05903352)
- Testing
- Stop antibiotic, Continue the antimicrobial treatment
- Where
- France
- Volunteers
- 328 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influenza A, Influenza B
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges…
- Conditions
- Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs)
- Trial name
- TreatResp (NCT07314905)
- Testing
- Baloxavir
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Unity Health Toronto
SARS CoV 2 Infection, COVID-19 Breakthrough
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St.
- Conditions
- SARS CoV 2 Infection, COVID-19 Breakthrough, COVID-19 Recurrent
- Trial name
- CoVICIS (NCT06435403)
- Where
- 2 sites in Ethiopia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
Pneumonia
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days
A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia (CAP)…
- Trial name
- COBRA II (NCT00237445)
- Testing
- telithromycin, azithromycin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Sanofi
Community-acquired Pneumonia
DiagNostic Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia
Rationale: Uncertainty in the clinical and etiological diagnosis of community-acquired pneumonia (CAP) often leads to incorrect treatment and unnecessary use of broad-spectrum antibiotics.
- Trial name
- CAP-NEXT (NCT03360851)
- Testing
- low-dose CT, PoC-PCR
- Where
- 7 sites in Netherlands
- Volunteers
- 3,555 people
- Sponsor
- MJM Bonten
COVID-19, Vaccine Hesitancy
Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
The purpose of this community-engaged study is to test the ability of county-level strategies to increase uptake of COVID-19 vaccination.
- Trial name
- K-VAC (NCT06505993)
- Testing
- Health Communication, Health Communication + Structural
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Marc Kiviniemi
Covid19
Community-based Post-exposure Prophylaxis for COVID-19
Specifically identified Ayurvedic preparations is recommended by ministry of AYUSH as post-exposure prophylaxis to efficaciously prevent a negative person who has come into contact with COVID-19-positive.
- Trial name
- NCT04920773
- Testing
- Guduchi Ghanvati, Standard guidelines
- Where
- 2 sites in India
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- NMP Medical Research Institute
Covid19
A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19
The COVID-19 pandemic is considered as the most crucial global health concern of the century. Given the complex interaction of physical and social factors on fast spreading infection, there have been increasing calls for…
- Trial name
- NCT04621903
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Aarogyam UK
Pneumonia
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia
Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired…
- Trial name
- NCT00431678
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Levofloxacin + Ceftriaxone
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 738 people
- Sponsor
- Bayer
Community-acquired Pneumonia
Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Pneumonia
The purpose of the study is to compare the clinical efficacy of amoxicillin given twice or three times a day to children with non-severe community-acquired pneumonia.
- Trial name
- PNEUMOPACEf (NCT01200706)
- Testing
- Amoxicillin
- Where
- Brazil
- Volunteers
- 820 people
- Sponsor
- Federal University of Bahia
Community-Acquired Bacterial Pneumonia (CABP)
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
- Trial name
- NCT01198626
- Testing
- JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 32 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Childhood Diarrhea, Childhood Pneumonia
Community Mobilization and Incentivization for Childhood Diarrhea and Pneumonia
Childhood diarrhea and pneumonia remains the leading cause of mortality among children under five years of age in Pakistan. The prevalence of diarrhea in Pakistan has increased from 15% in 1990 to 23% in 2013 while there has been…
- Conditions
- Childhood Diarrhea, Childhood Pneumonia, Community Mobilisation, Sanitation and Hygiene
- Trial name
- CoMIC (NCT03594279)
- Testing
- Community Mobilization, Community Mobilization and Community Incentive
- Where
- Pakistan
- Volunteers
- 48 people
- Sponsor
- Aga Khan University
Malaria, Diarrhea
Integrated Community Case Management Study in Eastern Province, Zambia
This study will provide important evidence to the Ministry of Community Development, Mother and Child Health (MCDMCH) and the Ministry of Health (MOH) on how to effectively implement iCCM with a focus on improving both the flow…
- Conditions
- Malaria, Diarrhea, Pneumonia
- Trial name
- NCT02866097
- Testing
- mHealth inventory management, Supportive supervision, ICCM current standard of care
- Where
- Zambia
- Volunteers
- 3,840 people
- Sponsor
- Zambia Center for Applied Health Research and Development
Dysphagia, Pneumonia
Oropharyngeal Dysphagia in Patients With Community Acquired Pneumonia
This study investigates relationship between community acquired pneumonia and oropharyngeal dysphagia in patients admitted to a department of respiratory medicine in Northern Denmark.
- Trial name
- NCT01974089
- Testing
- Dysphagia
- Where
- Denmark
- Volunteers
- 154 people
- Sponsor
- Regionshospital Nordjylland